This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2005.02.093v3 46/6/1019    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (33) Citing Articles via Google Scholar Google Scholar Articles by Doehner, W. Articles by Anker, S. D. Search for Related Content PubMed PubMed Citation Articles by Doehner, W. Articles by Anker, S. D.

CLINICAL RESEARCH: HEART FAILURE AND CARDIAC TRANSPLANT

Impaired Insulin Sensitivity as an Independent Risk Factor for Mortality in Patients With Stable Chronic Heart Failure

Wolfram Doehner, MD, PhD^_*,,_*, Mathias Rauchhaus, MD, PhD, Piotr Ponikowski, MD, PhD, Ian F. Godsland, PhD, Stephan von Haehling, MD^_*,,,, Darlington O. Okonko, BSc^_*, Francisco Leyva, MD^_*,, Anthony J. Proudler, PhD, Andrew J.S. Coats, DM^|| and Stefan D. Anker, MD, PhD^_*,

^_* Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College, London, United Kingdom
Division of Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany
Cardiology Department, Clinical Military Hospital, Wroclaw, Poland
Wynn Department of Metabolic Medicine, Division of Medicine, Imperial College, London, United Kingdom
^|| Faculty of Medicine, University of Sydney, Sydney, Australia.

Manuscript received December 1, 2004; revised manuscript received February 9, 2005, accepted February 14, 2005.

^_* Reprint requests and correspondence: Dr. Wolfram Doehner, Division of Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany. (Email: wolfram.doehner{at}charite.de).

Impaired Insulin Sensitivity as an Independent Risk Factor for Mortality in Patients With Stable Chronic Heart Failure

Wolfram Doehner, Mathias Rauchhaus, Piotr Ponikowski, Ian F. Godsland, Stephan von Haehling, Darlington O. Okonko, Francisco Leyva, Anthony J. Proudler, Andrew J. S. Coats, Stefan D. Anker

In chronic hart failure (CHF), impaired insulin sensitivity (S_I) indicates abnormal energy metabolism and is related to decreased exercise capacity and muscle fatigue. The relationship between insulin resistance and survival in CHF has not been established. We prospectively studied 105 male patients with CHF during a mean follow-up period of 44 ± 4 months. Lower S_I relates to higher mortality, independent of body composition and established prognosticators implicating a pathophysiologic role for S_I in CHF. Therapeutically targeting impaired S_I may potentially be beneficial in patients with CHF.

OBJECTIVES: The aim of this study was to determine the significance of insulin resistance as an independent risk factor for impaired prognosis in patients with chronic heart failure (CHF).

BACKGROUND: In CHF, impaired insulin sensitivity (S_I) indicates abnormal energy metabolism and is related to decreased exercise capacity and muscle fatigue. The relationship between insulin resistance (i.e., low S_I) and survival in patients with CHF has not been established.

METHODS: We prospectively studied 105 male patients with CHF due to ischemic (63%) or non-ischemic (37%) etiology. All patients were in clinically stable condition (age 62 ± 1 year, New York Heart Association [NYHA] functional class 2.6 ± 0.1, left ventricular ejection fraction [LVEF] 28 ± 2%, peak oxygen uptake [VO₂] 18.2 ± 0.7 ml/kg/min). Insulin sensitivity was assessed from glucose and insulin dynamic profiles during an intravenous glucose tolerance test using the minimal model technique.

RESULTS: During a mean follow-up period of 44 ± 4 months, 53 patients (50%) died. Patients with S_I below the median value (median: 1.82 min^–1·µU·ml^–1·10⁴; n = 52) had worse survival (at two years 61% [range 47% to 74%]) than patients with S_I above the median value (n = 53; at two years 83% [range 73% to 93%]; risk ratio [RR] 0.38, 95% confidence interval [CI] 0.21 to 0.67; p = 0.001). Both patient groups were similar in terms of age, NYHA functional class, and body composition parameters (dual-energy X-ray absorptiometric scan; p > 0.2), but patients with a lower S_I had a lower LVEF (24 ± 2% vs. 33 ± 3%) and peak VO₂ (16.8 ± 1.0 ml/kg/min vs. 19.7 ± 1.0 ml/kg/min; both p < 0.05). On univariate Cox analysis, higher S_I predicted better survival (RR 0.56, 95% CI 0.35 to 0.89; p = 0.015). On stepwise multivariate analysis, S_I predicted mortality independently of other variables.

CONCLUSIONS: In patients with CHF, lower S_I relates to higher mortality, independent of body composition and established prognosticators. Impaired S_I may have implications in the pathophysiology of CHF disease progression. Therapeutically targeting impaired insulin sensitivity may potentially be beneficial in patients with CHF.

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   BMI = body mass index   CHF = chronic heart failure   CI = confidence interval   DEXA = dual-energy X-ray absorptiometry   ivGTT = intravenous glucose tolerance test   LVEF = left ventricular ejection fraction   NYHA = New York Heart Association   RR = risk ratio   SI = insulin sensitivity   VO2 = oxygen uptake

This article has been cited by other articles:

				L. Sacca Heart Failure as a Multiple Hormonal Deficiency Syndrome Circ Heart Fail, March 1, 2009; 2(2): 151 - 156. [Full Text] [PDF]

				D. J. Fazakerley, S. P. Lawrence, V. A. Lizunov, S. W. Cushman, and G. D. Holman A common trafficking route for GLUT4 in cardiomyocytes in response to insulin, contraction and energy-status signalling J. Cell Sci., March 1, 2009; 122(5): 727 - 734. [Abstract] [Full Text] [PDF]

				H. T.F. Facundo and S. P. Jones AMP-Dependent Protein Kinase Activators: Not Just for Diabetes? Circ. Res., February 13, 2009; 104(3): 282 - 284. [Full Text] [PDF]

				R. T. Zamanian, G. Hansmann, S. Snook, D. Lilienfeld, K. M. Rappaport, G. M. Reaven, M. Rabinovitch, and R. L. Doyle Insulin resistance in pulmonary arterial hypertension Eur. Respir. J., February 1, 2009; 33(2): 318 - 324. [Abstract] [Full Text] [PDF]

				H. Tuunanen, E. Engblom, A. Naum, K. Nagren, M. Scheinin, B. Hesse, K.E. Juhani Airaksinen, P. Nuutila, P. Iozzo, H. Ukkonen, et al. Trimetazidine, a Metabolic Modulator, Has Cardiac and Extracardiac Benefits in Idiopathic Dilated Cardiomyopathy Circulation, September 16, 2008; 118(12): 1250 - 1258. [Abstract] [Full Text] [PDF]

				W. Doehner, S. von Haehling, and S. D. Anker Insulin resistance in chronic heart failure. J. Am. Coll. Cardiol., July 15, 2008; 52(3): 239 - 239. [Full Text] [PDF]

				M. R. MacDonald, M. C. Petrie, N. M. Hawkins, J. R. Petrie, M. Fisher, R. McKelvie, D. Aguilar, H. Krum, and J. J.V. McMurray Diabetes, left ventricular systolic dysfunction, and chronic heart failure Eur. Heart J., May 2, 2008; 29(10): 1224 - 1240. [Abstract] [Full Text] [PDF]

				C Berry, M Brett, K Stevenson, J J V McMurray, and J Norrie Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure Heart, March 1, 2008; 94(3): 296 - 304. [Abstract] [Full Text] [PDF]

				C. V. Leier and G. J. Haas Diabetes and Heart Failure: The Role of Thiazolidinediones in Managing These Partners in Crime J. Am. Coll. Cardiol., July 3, 2007; 50(1): 37 - 39. [Full Text] [PDF]

				S. von Haehling, W. Doehner, and S. D Anker Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure Cardiovasc Res, January 15, 2007; 73(2): 298 - 309. [Abstract] [Full Text] [PDF]

				M. Lainscak, W. Doehner, and S. D. Anker Metabolic disturbances in chronic heart failure: A case for the "macho" approach with testosterone?! Eur J Heart Fail, January 1, 2007; 9(1): 2 - 3. [Abstract] [Full Text] [PDF]

				C. J. Malkin, T. H. Jones, and K. S. Channer The effect of testosterone on insulin sensitivity in men with heart failure Eur J Heart Fail, January 1, 2007; 9(1): 44 - 50. [Abstract] [Full Text] [PDF]

				J. D. Horowitz and J. A. Kennedy Time to Address the Cardiac Metabolic "Triple Whammy": Ischemic Heart Failure in Diabetic Patients J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2232 - 2234. [Full Text] [PDF]

				T. Karhausen, M. Stockburger, W. Doehner, and S. D. Anker Questions in Cardiac Resynchronization Therapy: Metabolic Implications J. Am. Coll. Cardiol., August 1, 2006; 48(3): 591 - 592. [Full Text] [PDF]

				A. J. Murray, C. A. Lygate, M. A. Cole, C. A. Carr, G. K. Radda, S. Neubauer, and K. Clarke Insulin resistance, abnormal energy metabolism and increased ischemic damage in the chronically infarcted rat heart Cardiovasc Res, July 1, 2006; 71(1): 149 - 157. [Abstract] [Full Text] [PDF]

				S. von Haehling, W. Doehner, and S. D. Anker Obesity and the Heart: A Weighty Issue J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2274 - 2276. [Full Text] [PDF]

				J. Yang and G. D. Holman Long-Term Metformin Treatment Stimulates Cardiomyocyte Glucose Transport through an AMP-Activated Protein Kinase-Dependent Reduction in GLUT4 Endocytosis Endocrinology, June 1, 2006; 147(6): 2728 - 2736. [Abstract] [Full Text] [PDF]

				Y. Liao, S. Takashima, H. Zhao, Y. Asano, Y. Shintani, T. Minamino, J. Kim, M. Fujita, M. Hori, and M. Kitakaze Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice Cardiovasc Res, April 1, 2006; 70(1): 107 - 116. [Abstract] [Full Text] [PDF]

				J. Butler More Risk Factors Affecting Heart Failure Outcomes!: Time for Hope or Despair? J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1027 - 1028. [Full Text] [PDF]